Ahead of the upcoming American Society of Hematology annual meeting, a multicenter study published in the Journal of Clinical ...
Earlier this year, the FDA approved a new frontline option for patients with diffuse large B-cell lymphoma (DLBCL): the antibody-drug conjugate polatuzumab vedotin (Polivy) in combination with ...
In this video, Catherine S. Diefenbach, MD, discusses highlights from the 2025 Lymphoma, Leukemia & Myeloma Congress.
Seattle Genetics (NASDAQ:SGEN) initiates a 110-subject, randomized, open-label, multi-center Phase 2 clinical trial assessing ADCETRIS (brentuximab vedotin), in combination with Roche's (OTCQX:RHHBY) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback